Rising exports, price hike, improving mix not enough to offset costs
Stock trading at 74% premium to Hero at valuation of 24.5x its FY23 earnings
While revenue growth was robust in Q4, weak mix, costs dented profits
Demand trajectory, market share losses are other concerns
The stock has been underperforming recent months and trades at a discount to peers
Valuations are, however, rich limiting the upside potential
Some brokerages prefer Metropolis given higher realisation, revenue growth trajectory
In the domestic market, growth is expected to come from Covid-related drugs
After a strong finish to FY21, the key trigger for the stock would be the growth metrics the company will deliver in FY22
Higher raw material costs will put pressure on profitability
Street expects an upward revision in growth guidance; valuation divergence with TCS to narrow
Debt reduction key if the stock is to fetch higher valuation multiples
Higher commodity prices could worsen its margin profile
Recovery in the African and Latin American markets should help exporters post better growth than the domestic market
Access to the private market, international sales are other factors that will impact margins
Valuations, PVC price moderation may, however, keep the stock under pressure
Final nod from DCGI soon, jab likely at $3/dose
March quarter performance is expected to be strong on low base, price hikes
Product mix and salary reinstatement could put pressure on margins
Market share improvement, uptick in margins to sustain gains over the medium term